Your fact-checks will appear here
Antiparasite medication
Ivermectin is an antiparasitic drug with approved human uses (e.g., scabies, strongyloidiasis) and long-standing veterinary formulations; several U.S. states moved in 2025 to allow over‑the‑counter (O...
Repeated, guideline-directed ivermectin dosing has documented long-term public-health benefits against parasitic diseases (notably onchocerciasis), but it is not risk-free: long-term community program...
Ivermectin can cause common, usually mild adverse effects such as headache, nausea, dizziness, diarrhea, and skin rash when given at approved human doses . Serious but rare harms include neurological ...
Ivermectin normally does not cross the human blood–brain barrier (BBB) because P‑glycoprotein (ABCB1/MDR1) at the BBB effluxes the drug; knockout or defective ABCB1 leads to brain levels tens of times...
Serious neurologic adverse events (encephalopathy, seizures, coma, persistent coma, ataxia) after ivermectin are uncommon but documented, and risk clusters around particular parasitic coinfections (no...
Ivermectin is an approved, effective antiparasitic medicine for specific human conditions — notably intestinal strongyloidiasis and onchocerciasis, and in some regions for scabies and topical rosacea ...
is the benzimidazole most advanced in human cancer testing and has been combined with chemotherapy in early‑phase clinical studies—most notably with in high‑grade glioma—showing safety signals and sug...
When patients take multiple prescription drugs, ivermectin dosing is not a one-size-fits-all calculation but a weight-based starting point (typically ~150–200 mcg/kg) that must be reconsidered in ligh...
Ivermectin commonly interacts with drugs that affect CYP3A4 metabolism and P‑glycoprotein (P‑gp) transport, and with substances that add central‑nervous‑system (CNS) depression or alter bleeding risk;...
Ivermectin’s pharmacokinetics are influenced by body composition and age in ways that often affect distribution and timing more than peak systemic exposure, while P‑glycoprotein (P‑gp) activity and CY...
Ivermectin in adults is associated with a spectrum of recognized adverse reactions that can be neurological (confusion, seizures, encephalopathy) and allergic or cutaneous (rash, pruritus, severe hype...
There is no established single parasite proven to cause type 2 diabetes, and therefore no scientifically supported claim that ivermectin “kills the parasite that is associated with type 2 diabetes.” S...
Ivermectin’s standard, evidence-backed human dosing for parasitic infections is generally in the 150–200 micrograms per kilogram (mcg/kg) single-dose range, with some indications and expert guides ext...
Ivermectin dosing is tailored first to the parasite being treated and the patient’s body weight, with single doses typically in the 150–200 μg/kg range and repeat doses or maintenance schedules determ...
Clinical human data on ivermectin as an anticancer therapy are very limited: most evidence is preclinical (cell lines and animal models) showing antiproliferative, pro‑apoptotic and immune‑modulating ...
Ivermectin’s oral pharmacokinetics — fat‑soluble, large volume of distribution, peak plasma ~4 hrs with enterohepatic recycling and primarily fecal excretion — constrain how high plasma and tissue con...
People with liver disease should use extra caution with antiparasitic drugs: ivermectin is generally well tolerated but can cause transient liver enzyme elevations and rare clinically apparent liver i...